‘Cell-in-a-Box’ Diabetes treatment enters new phase, UTS to do research now

PharmaCyte Biotech, a clinical stage biotechnology company has announced that its new cancer and diabetes treatment method using live-cell encapsulation technology, Cell-in-a-Box, will be taken up by the University of Technology Sydney (UTS) in Australia.

Announcing its contract with the varsity, PharmaCyte Biotech said it will provide funding for the study on treatment of insulin-dependent diabetes that is comprised of proprietary human non-pancreatic insulin-producing cells (Melligen cells) to be encapsulated using its cellulose-based live cell encapsulation technology known as Cell-in-a-Box.

The Research Services Agreement is designed to provide funding to UTS that will permit Prof. Ann Simpson, the world’s foremost authority on the Melligen cells, and her colleagues at UTS to conduct pivotal studies with Melligen cells in order to help fully characterize the parameters by which these cells produce insulin “on demand” when they are encapsulated using the Cell-in-a-Box technology.

The Consulting Contract will allow Prof. Simpson to devote a sufficient amount of her time to working with PharmaCyte Biotech and its international Diabetes Consortium as it pursues the development of its diabetes treatment for insulin dependent diabetes.

“Kenneth L. Waggoner, PharmaCyte Biotech’s Chief Executive Officer, commented, “The Research Services Agreement and Prof. Simpson’s Consulting Contract are extremely important and very necessary as PharmaCyte Biotech pursues its goal of developing a treatment for insulin-dependent diabetes.”

Prof. Simpson will be a consultant as she is also a founding member of PharmaCyte’s Diabetes Consortium, with expertise in dealing with the Melligen cells.

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.